Relmada Downgraded at Truist, Guggenheim in wake of depression candidate failure

Oct. 14, 2022 12:00 PM ETRelmada Therapeutics, Inc. (RLMD)By: Jonathan Block, SA News Editor1 Comment

New York Stock Exchange, Wall st, New York, USA

Matteo Colombo

  • Truist and Guggenheim have downgraded Relmada Therapeutics (NASDAQ:RLMD) to hold and neutral, respecitvely, following the failure of phase 3 depression REL-1017.
  • Truist lowered its price target to $10 from $90 (~54% upside based on Thursday's close) while Guggenheim doesn't have a target.

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.